VEGF 936C > T Polymorphism and Association of BI-RADS Score in Women with Suspected Breast Cancer

M. Wehrschuetz¹, H. Schöllnast¹, E. Wehrschuetz¹, W. Renner² and G. Luschin³

¹Department of Radiology, Medical University Graz, Graz, Austria. ²Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria. ³Department of Obstetrics and Gynecology, Medical University Graz, Graz, Austria. Email: martin.wehrschuetz@meduni-graz.at

Abstract
Purpose: Vascular endothelial growth factor (VEGF) is a potent regulator of angiogenesis and thereby involved in the development and progression of solid tumors. A 936C > T polymorphism in the VEGF gene has been associated with reduced VEGF plasma levels. Purpose of the present study was to analyze the potential association between VEGF genotype and radiological appearance of breast lesions by mammography.

Materials and Methods: Fifty two women with 54 suspected breast lesions were analyzed by the use of mammography with the standard breast imaging reporting and data systems (BI-RADS). Germline VEGF genotype was determined in all subjects by allele-specific digestion of amplification products. An open biopsy was performed on all lesions.

Results: VEGF CC, CT and TT genotypes were found in 41 (79%), 9 (17%) and 2 (4%) patients. By mammography 26, 16 and 12 suspected breast lesions were classified as BI-RADS scores 3, 4 and 5, respectively. Both carriers of the TT genotype were classified as BI-RADS 5, whereas among CT or CC carriers, BI-RADS scores 3, 4 and 5 were found in 26, 16 and 10 subjects (P < 0.026).

Conclusion: The VEGF 936C > T polymorphism seems to be associated with a high BI-RADS score in women with suspicious breast lesions.

Keywords: vascular endothelial growth factor, VEGF, breast cancer, polymorphism
Introduction
Vascular endothelial growth factor (VEGF) is an important regulator of vasculogenesis and angiogenesis with a specific mitogenicity for endothelial cells.\textsuperscript{1,2} In addition, VEGF can increase capillary permeability, dilate arteries and attract monocytes chemotactically.\textsuperscript{3,4} VEGF is a disulfide-bonded dimeric glycoprotein, sharing close sequence homology with VEGF-B and VEGF-C and placenta growth factor, and lower sequence homology with platelet-derived growth factor.\textsuperscript{5,6} Strong expression of VEGF has been observed in a variety of tissues, including tissues of the female reproductive system, ischemic tissues, tumours and transformed cell lines.\textsuperscript{7}

Breast cancer is the most frequently diagnosed cancer in Western societies, with a lifetime incidence of about 10%–13% among women.\textsuperscript{8,9} Mammography is the accepted method for screening to diagnose small breast cancers. The present study intended to analyze the potential association between VEGF genotype and the radiological/mammographic assessment of breast lesions.

Materials and Methods
Subjects
Fifty-two women (age range, 30–82; mean age, 54.5 ± 11.8 years) were prospectively enrolled in our trial between October 2002 and March 2003. Inclusion criteria were 1) breast symptoms, 2) no history of breast cancer, 3) female sex, 4) written informed consent. Exclusion criteria were 1) history of breast cancer, 2) pregnancy and 3) age under 18 years. All women had a full diagnostic work up including clinical examination, mammography, breast ultrasound and all had a preoperative localisation procedure under stereotactic or ultrasound guidance. Each woman provided a blood sample preoperatively for further genetic analysis. Each sample was marked with a serial number to assure data protection of personal data. The study was approved by the ethics committee of the Medical University of Graz. TNM classification, lymph node status, ER, PR and Her2/neu were routinely defined by our institute of pathology and elaborated for the included patients by the study authors.

Statistical Analysis
P-values for the comparison of the BI-RADS III, IV, V and VEGF 936C > T polymorphism and the comparison of VEGF 936C > T polymorphism and TNM classification, lymph node status, ER, PR and Her2/neu were calculated with Pearson’s Chi square test and Wilcoxon-Mann-Whitney test using the exact test option in StatXact 4.0.1 (Cytel Software Corp., Cambridge, MA). Threshold for significance was \( p < 0.05 \).

Imaging and Evaluation
Mammography was performed with a Siemens Mammatom 3000 (Siemens Medical System, Erlangen, Germany). A dedicated Agfa film processor with an extended (2-minute) processing cycle was employed with Adefo chemistry at 34 °C development temperature. A commercial single-emulsion mammography film with standard screens and carbon cassettes were used (previously MicrovisionCi, Sterling, USA—now Agfa, Belgium) at a mammography site approved by the Austrian Ministry of Public Health. Two experienced radiologists analyzed the mammography images. All images were classified by the standard breast imaging reporting and data systems (BI-RADS).\textsuperscript{10} Breast ultrasound was performed at the discretion of the radiologists with a Logiq 700 MR (General Electric Medical System, Milwaukee, USA). A digital system (OPDIMA, Siemens Medical System, Erlangen, Germany) was used for preoperative stereotactic localisation.

A microbiologist specialised in genetics determined the patients’ genotypes as follow:

For genetic analyses, genomic DNA was isolated from venous blood by standard methods and stored at 4 °C. A 198 bp fragment containing the polymorphic site was amplified by polymerase chain reaction (PCR) using 5’-AAGGAAGAGAGACTCTGCAG-3’ as forward and 3’-TATGTGGGTGGGTGTCAC AGG-3’ as reverse primer. The PCR product was digested with restriction endonuclease NlaIII (New England Biolab); fragments were analyzed on 2.0% agarose gels stained with ethidium bromide. The C allele remained uncut, while the T allele was cut into two fragments of 114 and 84 bp. For each set of reactions, a negative control containing \( \text{H}_2\text{O} \) instead of DNA to check for contamination and a positive control (sample with homozygous TT genotype) to check for complete digestion were added.

Results
The study consisted of 52 women with 54 breast lesions. VEGF genotype was determined for all
subjects. With mammography, 26, 16 and 12 suspected breast lesions were classified as BI-RADS category 3, 4 and 5, respectively. VEGF CC, CT and TT genotypes were found in 41 (79%), 9 (17%) and 2 (4%) patients. The two carriers of the TT genotype were classified as BI-RADS 5 Figures 1 and 2; among CT or CC carriers, BI-RADS scores 3, 4 and 5 were found in 26, 16 and 10 subjects, respectively \( (p < 0.026) \) (Table 1). In all, 28 lesions (51.8%) were considered to be cancerous. No correlation was found between the 936C > T gene polymorphism of VEGF and tumor size and histological grading \( (p < 0.83) \), lymph node status \( (p < 0.54) \), estrogen receptor status \( (p < 1.1) \), progesterone receptor status \( (p < 0.76) \), or HER2/neu receptor status \( (p < 0.8) \) (Tables 2, 3). The sensitivity and the specificity were 86% and 97%, respectively, with 92% accuracy. Histological diagnosis was the gold standard.

**Discussion**

The aetiology of breast cancer is still not fully understood. Besides age at menarche and menopause, diet, reproductive history, oestrogen administration and genetic factors have been suggested as risk factors.\(^{11–15}\) Many women will at some time have breast symptoms, especially between 40–70 years of age; the risk of developing breast cancer is gradually increasing in this age range. During a given 10-year period, it is estimated that 13%–16% of women will seek medical advice due to breast symptoms.\(^ {16,17}\)

| Allele | BI-RADS III | BI-RADS IV | BI-RADS V |
|--------|-------------|-------------|-------------|
| CC + CT | 26 | 16 | 10 |
| TT | 0 | 0 | 2 | \( p < 0.026 \) |

Table 1. Comparison of BI-RADS III, IV, V and VEGF 936C > T polymorphism in patients with breast symptoms.

Our intention was to analyze the potential association between VEGF genotype and mammography findings to provide information to supplement the clinician's repertoire of breast palpation, imaging techniques, and biopsy.

Appropriate management of breast findings is very important for the primary physician regarding a reported diagnosing rate for breast cancer of 4% of patients with breast symptoms.\(^ {16}\) Pooled data from screening studies estimate sensitivity of 54%.\(^ {18}\) There is considerable interobserver variability in detection rates and interpretation. Only 25% interobserver agreement was shown in a study involving experienced breast surgeons who evaluated breast abnormalities in 100 consecutive women with breast symptoms. Biopsy was recommended in 28%–39% of these cases, but only in 17% were the surgeons in agreement.\(^ {19}\)

With breast induration, Kaiser et al found that mammography alone had a sensitivity of 60% for invasive breast carcinoma. The specificity of mammograms upon initial imaging was 94%
and the negative predictive value was 97%.\textsuperscript{20} The usefulness of breast US in detecting carcinomas was demonstrated by Butler et al.,\textsuperscript{21} who detected 87.7% of mammographically subtle or invisible lesions.

We find that it can be very difficult to evaluate breast symptoms by palpation, especially in patients who have previously undergone biopsy procedures; these can entail postsurgical sequelae such as breast scarring, fat necrosis, architectural distortion and skin changes that can mislead the radiologist. We so hypothesized that VEGF in general and the 936C\textsuperscript{T} polymorphism in particular could help radiologists resolve these ambiguities.

In our cohort, both carriers of the TT genotype were classified as BI-RADS 5, whereas among CT or CC carriers, BI-RADS scores 3, 4 and 5 were found in 26, 16 and 10 subjects, respectively (P < 0.026). Carriers of the TT allele with breast symptoms thus face a significantly higher risk for breast cancer than those without that allele and, if supported by mammography and ultrasound, should be strongly urged to undergo biopsy due to their greater likelihood of having breast cancer with a high-grade BIRADS than patients carrying the CC or the CT allele, as suggested by the literature.\textsuperscript{22} Erolglu et al. failed, however to find an association between the 936C/T polymorphism and clinicopathological characteristics,\textsuperscript{23} although it has been demonstrated beyond reasonable doubt that VEGF plays an important role in breast cancer,\textsuperscript{24} and there appears to be a significant positive association between HER-2/neu and VEGF expression.\textsuperscript{25} In any case, as our data show statistical significance in the comparison of 936C/T polymorphism and BI-RADS scores in mammography, we propose a potential association of the 936C/T polymorphism with mammographic appearance of breast lesions in women suffering breast symptoms.

A limitation of our study is its small size. Further prospective trials should clarify the role of VEGF and potential morphologic coherences of the VEGF 936C \textgreater{} T polymorphism and mammographic appearance of breast lesions in women suffering breast symptoms.

**Acknowledgement**

We want to thank Mrs. Genie Lamont for revising the manuscript.

**Disclosures**

The authors report no conflicts of interest.

**References**

1. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.

2. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991;266:11947–54.

3. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983–5.

4. Claus M, Gerlach M, Gerlach H, et al. Vascular permeability factor. A tumor derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med. 1990;172:1535–45.
5. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. *Science*. 1989;246:1309–12.

6. Magilione D, Guerriero V, Viglietto G, Delli Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. *Proc Natl Acad Sci U S A*. 1991;88:9267–71.

7. Iruela Arispe ML, Dvorak HF. Angiogenesis: A dynamic balance of stimulators and inhibitors. *Thromb Haemost*. 1997;78:672–7.

8. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. *CA Cancer J Clin*. 2000;50:7.

9. Ries LAG, Kosary CL, Hankey BF. SEER Cancer Statistics Review, 1973–1996. Bethesda, MD: National Cancer Institute, 1999.

10. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS) 3rd ed. Reston, Va: American College of Radiology, 1998.

11. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. *Lancet*. 1997;350:1047–59.

12. Lee SM, Park JH, Park HJ. Breast cancer risks in Korean women. A literature review. *Int Nurs Rev*. 2008 (Sept);55(3):355–9.

13. Hulka BS, Stark AT. Breast Cancer: cause and prevention. *Lancet*. 1995;346:883–7.

14. Kelsey JL. Breast cancer epidemiology: summary and future directions. *Epidemiol Rev*. 1993;15:256–63.

15. World Cancer Research Fund—American Institute of Cancer Research (1997). Food, Nutrition and the Prevention of Cancer: A global Perspective. Banta Book Group, Mebasha USA, S.252.

16. Barton MB, Elmore JG, Fletcher SW. Breast symptoms among women enrolled in a health maintenance organisation: frequency, evaluation and outcome. *Ann Intern Med*. 1999;130:651–7.

17. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. *N Engl J Med*. 1998;338:1089–96.

18. Barton MB, Harris RP, Fletcher SW. Does this patient have breast cancer? The screening clinical breast examination: Should it be done? *How? JAMA*. 1999;282:1270–80.

19. Boyd NF, Sutherland HJ, Fish EB, Hiraki GY, Lickley HLA, Maurer VE. Prospective evaluation of physical examination of the breast. *Am J Surg*. 1981;142:331–4.

20. Kaiser JS, Helvie MA, Blacklaw RL, Roubidoux MA. Palpable breast thickening: Role of Mammography and US in Cancer Detection. *Radiology*. 2002;223:839–44.

21. Butler RS, Venta LA, Wiley EL, Ellis RL, Dempsey PJ, Rubin E. Sonographic evaluation of infiltrating lobular carcinoma. *AJR Am J Roentgenol*. 1999;172:325–33.

22. Krippel P, Langsenlehner U, Remmer W, et al. A common 936C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. *Int J Cancer*. 2003;10:106(4):468–71.

23. Erolglu A, Oztürk A, Cam R, Akar N. Vascular endothelial growth factor gene 936C/T polymorphism in breast cancer patients. *Med Oncol*. 2008;25(1):54–5.

24. Manders P, Boex LV, Tjan Heijnen VC, Span PN, Sweep CG. Cascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. *Cancer*. 2003 Nov 15;98(10):2125–32.

25. Konceny GE, Meng YG, Untech M, et al. Association between HER2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. *Clin Cancer Res*. 2004 Dec 15;10(24):8752–3.

---

**Publish with Libertas Academica and every scientist working in your field can read your article**

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

**Your paper will be:**
- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

[http://www.la-press.com](http://www.la-press.com)